CCR5 and pancreatic ductal adenocarcinoma: However, combining CXCR4 or CCR5 antagonists with anti-PD1 immunotherapy has shown promising results in clinical studies in patients with colorectal cancer and pancreatic ductal adenocarcinoma [63,64].